In Vitro ADME Testing Services Market, 2019-2030

The early stages of drug discovery research, which include the identification of a relevant biological target and a viable lead compound with therapeutic potential, play a crucial role in the overall success of a drug candidate in both preclinical and clinical studies. It is also important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent in R&D initiatives in the pharmaceutical/biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small fraction of early-stage therapeutic candidates are able to make it past preclinical evaluation. According to a study conducted on terminated drug development programs, the high rate of failure of drugs in clinical trials was primarily attributed to problems associated with their pharmacokinetic profiles, absorption, distribution, metabolism and excretion (ADME) properties and inherent toxicity. As a result, the industry is currently under tremendous pressure to not only meet the expectations of a growing patient population but to also identify ways to mitigate the risks associated with discovery programs of novel drug/therapy molecules.

Specifically, ADME studies are considered to be critical in establishing the safety and efficacy of drug candidates. Currently, there are a number of contract research organizations (CROs) that claim to have the necessary capabilities to offer in vitro ADME services. Over time, such service providers have grown to become an indispensable part of the pharmaceutical/biopharmaceutical market. Moreover, advances in combinatorial chemistry and high throughput screening in the last decade have made it possible to carry out early-stage ADME screening for a large number of compounds in a more cost and time efficient manner. In less than a decade, the ADME services industry has witnessed noteworthy consolidation, with many of the smaller players being acquired by more established firms in efforts to augment services portfolios and widen geographical reach. Further, given the growing demand for high-quality pharmacological interventions, and the cost and time-related benefits of outsourcing in vitro ADME research, the demand for CROs is projected to grow significantly in the foreseen future.

The ‘In Vitro ADME Testing Services Market, 2019-2030’ report features a comprehensive study of the current landscape of in vitro ADME testing service providers. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders across different global regions. Amongst other elements, the report includes:

A detailed assessment of the current market landscape, featuring a comprehensive list of over 90 CROs that offer in vitro ADME testing services, and analyses based on a number of parameters, such as year of establishment, headquarter location(s), company size, type of additional service(s) offered (in vivo ADME, in silico ADME and toxicology testing), range of assays offered within in vitro ADME service portfolio (blood to plasma ratio, Caco-2 permeability, cytochrome (CYP) enzyme induction / inhibition, metabolic stability, plasma protein binding, reaction phenotyping and others), type of molecule(s) (biologics and small molecules), and type of clientele (pharmaceutical / biotechnology companies and academic / research institutes).
A schematic logo landscape of in vitro ADME service providers, highlighting their geographical distribution (on the basis of location of headquarters) and company size (small-sized (1-50 employees), mid-sized (51-200 employees), large (201-1,000 employees), and very large (>1,000 employees)).
A discussion on the various outsourcing business models adopted in this domain, along with a list of key considerations that need to be taken into account by industry stakeholders while selecting a CRO partner.
Elaborate profiles of popular in vitro ADME testing service providers, featuring a brief overview of the company, its financial information (if available), information on in vitro ADME service(s) capabilities, and a comprehensive future outlook.
A comprehensive benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups, and thereby, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2005-2018, along with the geographical distribution of this activity. The analysis also features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.
A detailed discussion on the various regulatory guidelines related to in vitro ADME testing, which have been laid down by major international / regional regulatory bodies (namely European Medicine Agency (EMA), US Food and Drug Administration (USFDA), Ministry of Health, Labor and Welfare (MHLW), International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use, the Organisation for Economic Co-operation and Development (OECD), and World Health Organization (WHO)).

One of the key objectives of the report is to evaluate the current opportunity and the future potential of the in vitro ADME testing services market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. In addition, we have segmented the future opportunity across [A] different global regions (North America, Europe, Asia-Pacific and rest of the world), [B] type of services (absorption, distribution, metabolism and excretion), [C] type of assays (across 5+ categories), [D] type of molecule(s) (biologics and small molecules), [E] type of sponsor company (pharmaceutical / biotechnology companies and academic / research institutes) and [F] therapeutic areas (across 10+ categories). To account for the uncertainties associated with the in vitro ADME testing services market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions conducted with several stakeholders in this industry. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. The Drug Discovery and Development Process
3.3. Introduction to Absorption, Distribution, Metabolism and Excretion (ADME) Testing
3.3.1. Absorption
3.3.2. Distribution
3.3.3. Metabolism
3.3.4. Excretion
3.4. Importance of ADME Studies in Early Stage Research
3.5. Types of ADME Studies in Discovery and Preclinical Development
3.6. Types of Assays Used in ADME Testing
3.7. Types of ADME Testing Studies
3.7.1. In Vitro ADME Testing Studies
3.7.2. In Silico ADME Testing Studies
3.7.3. In Vivo ADME Testing Studies
3.8. Key Drivers for ADME Testing Studies
3.9. Concluding Remarks

4. GUIDE TO OUTSOURCING

4.1. Chapter Overview
4.2. Outsourcing ADME Testing Services
4.3. Guiding Models for Outsourcing
4.3.1. Transactional Outsourcing Model
4.3.2. Performance-based Outsourcing Model
4.3.3. Outcomes-based Outsourcing Model
4.3.4. Phase-dependent Outsourcing Model
4.4. Selecting a Contract Research Organization (CRO) Partner
4.4.1. Key Considerations
4.5. Role of CROs in Drug Development
4.5.1. Discovery and Preclinical Research
4.5.2. Early Clinical Research
4.5.3. Late Stage Clinical Research
4.6. Benefits of Outsourcing ADME Testing Services
4.7. Risks and Challenges Associated with Outsourcing ADME Testing Services
4.8. Concluding Remarks

5. MARKET LANDSCAPE

5.1. Chapter Overview
5.2. In Vitro ADME Testing Services: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Geographical Location
5.2.3. Analysis by Company Size
5.2.4. Analysis by Type of Service Offering
5.2.5. Analysis by Type of In Vitro ADME Assays
5.2.6. Analysis by Type of Molecule
5.2.7. Analysis by Type of Clientele
5.2.8. Logo Landscape: Distribution by Company Size and Location of Headquarters
5.3 In Silico ADME Testing Services: List of Industry Players

6. COMPANY PROFILES

6.1. Chapter Overview
6.2. Key Players based in North America
6.2.1. Albany Molecular Research (AMRI)
6.2.1.1. Company Snapshot
6.2.1.2. Financial Information
6.2.1.3. ADME Testing Specific Service Portfolio
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Charles River Laboratories
6.2.2.1. Company Snapshot
6.2.2.2. Financial Information
6.2.2.3. ADME Testing Specific Service Portfolio
6.2.2.4. Recent Developments and Future Outlook
6.2.3. Pharmaceutical Product Development (PPD)
6.2.3.1. Company Snapshot
6.2.3.2. ADME Testing Specific Service Portfolio
6.2.3.3. Recent Developments and Future Outlook
6.2.4. RTI International
6.2.4.1. Company Snapshot
6.2.4.2. Financial Information
6.2.4.3. ADME Testing Specific Service Portfolio
6.2.4.4. Recent Developments and Future Outlook
6.3. Key Players based in Europe
6.3.1. Eurofins Scientific
6.3.1.1. Company Snapshot
6.3.1.2. Financial Information
6.3.1.3. ADME Testing Specific Service Portfolio
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Evotec
6.3.2.1. Company Snapshot
6.3.2.2. Financial Information
6.3.2.3. ADME Testing Specific Service Portfolio
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Galapagos
6.3.3.1. Company Snapshot
6.3.3.2. Financial Information
6.3.3.3. ADME Testing Specific Service Portfolio
6.3.3.4. Recent Developments and Future Outlook
6.3.4. Tecan Group
6.3.4.1. Company Snapshot
6.3.4.2. Financial Information
6.3.4.3. ADME Testing Specific Service Portfolio
6.3.4.4. Recent Developments and Future Outlook
6.4. Key Players based in Asia-Pacific
6.4.1. GVK Biosciences
6.4.1.1. Company Snapshot
6.4.1.2. ADME Testing Specific Service Portfolio
6.4.1.3. Recent Developments and Future Outlook
6.4.2. Pharmaron
6.4.2.1. Company Snapshot
6.4.2.2. ADME Testing Specific Service Portfolio
6.4.2.3. Recent Developments and Future Outlook
6.4.3. Sai Life Sciences
6.4.3.1. Company Snapshot
6.4.3.2. ADME Testing Specific Service Portfolio
6.4.3.3. Recent Developments and Future Outlook
6.4.4. Shanghai Medicilon
6.4.4.1. Company Snapshot
6.4.4.2. ADME Testing Specific Service Portfolio
6.4.4.3. Recent Developments and Future Outlook
6.4.5. Syngene International
6.4.5.1. Company Snapshot
6.4.5.2. Financial Information
6.4.5.3. ADME Testing Specific Service Portfolio
6.4.5.4. Recent Developments and Future Outlook
6.4.6. WuXi AppTec
6.4.6.1. Company Snapshot
6.4.6.2. Financial Information
6.4.6.3. ADME Testing Specific Service Portfolio
6.4.6.4. Recent Developments and Future Outlook

7. BENCHMARK ANALYSIS

7.1. Chapter Overview
7.2. Benchmark Analysis: Methodology
7.3. Benchmark Analysis: Peer Groups
7.3.1. Peer Group I
7.3.2. Peer Group II
7.3.3. Peer Group III
7.3.4. Peer Group IV
7.3.5. Peer Group V
7.3.6. Peer Group VI
7.3.7. Peer Group VII
7.3.8. Peer Group VIII
7.4. Concluding Remarks

8. MERGERS AND ACQUISITIONS

8.1. Chapter Overview
8.2. In Vitro ADME Testing Services: Mergers and Acquisitions
8.2.1. Cumulative Year-wise Trend
8.2.2. Geographical Activity
8.2.3. Ownership Change Matrix
8.2.4. Most Active Players: Analysis by Number of Acquisitions
8.2.5. Key Value Drivers
8.2.6. Key Acquisitions: Deal Multiples

9. REGULATORY RECOMMENDATIONS AND GUIDELINES

9.1. Chapter Overview
9.2. Regulatory Guidelines Issued by International Regulatory Agencies
9.2.1. The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use
9.2.2. World Health Organization (WHO)
9.2.3. Organisation for Economic Co-operation and Development (OECD)
9.3. Regulatory Guidelines Issued by Regional Regulatory Agencies
9.3.1. United States Food and Drug Administration (USFDA), US
9.3.2. European Medicine Agency (EMA), Europe
9.3.3. Ministry of Health, Labour and Welfare (MHLW), Japan
9.4. In Vitro ADME Testing Service Providers: Information on Regulatory Approval

10. MARKET FORECAST

10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall In Vitro ADME Testing Services Market, 2019-2030
10.4. In Vitro ADME Testing Services Market: Distribution by Regions, 2019-2030
10.4.1. In Vitro ADME Testing Services Market in North America, 2019-2030
10.4.1.1. In Vitro ADME Testing Services Market in the US, 2019-2030
10.4.1.2. In Vitro ADME Testing Services Market in Canada, 2019-2030
10.4.2. In Vitro ADME Testing Services Market in Europe, 2019-2030
10.4.2.1. In Vitro ADME Testing Services Market in Germany, 2019-2030
10.4.2.2. In Vitro ADME Testing Services Market in France, 2019-2030
10.4.2.3. In Vitro ADME Testing Services Market in the UK, 2019-2030
10.4.2.4. In Vitro ADME Testing Services Market in Italy, 2019-2030
10.4.2.5. In Vitro ADME Testing Services Market in Spain, 2019-2030
10.4.2.6. In Vitro ADME Testing Services Market in Rest of Europe, 2019-2030
10.4.3. In Vitro ADME Testing Services Market in Asia-Pacific and Rest of the World, 2019-2030
10.4.3.1. In Vitro ADME Testing Services Market in Japan, 2019-2030
10.4.3.2. In Vitro ADME Testing Services Market in China, 2018-2028
10.4.3.3. In Vitro ADME Testing Services Market in India, 2019-2030
10.4.3.4. In Vitro ADME Testing Services Market in Rest of the World, 2019-2030
10.5. In Vitro ADME Testing Services Market: Distribution by Type of Services, 2019-2030
10.5.1. In Vitro ADME Testing Services Market for Absorption Testing, 2019-2030
10.5.2. In Vitro ADME Testing Services Market for Distribution Testing, 2019-2030
10.5.3. In Vitro ADME Testing Services Market for Metabolism Testing, 2019-2030
10.5.4. In Vitro ADME Testing Services Market for Excretion Testing, 2019-2030
10.6. In Vitro ADME Testing Services Market: Distribution by Type of Assays, 2019-2030
10.6.1. In Vitro ADME Testing Services Market for Caco-2 Permeability Assay, 2019-2030
10.6.2. In Vitro ADME Testing Services Market for Protein Binding Assay, 2019-2030
10.6.3. In Vitro ADME Testing Services Market for Metabolic Stability / Clearance Assay, 2019-2030
10.6.4. In Vitro ADME Testing Services Market for Enzyme Induction Assay, 2019-2030
10.6.5. In Vitro ADME Testing Services Market for Enzyme Inhibition Assay, 2019-2030
10.6.6. In Vitro ADME Testing Services Market for Other Assays, 2019-2030
10.7. In Vitro ADME Testing Services Market: Distribution by Type of Molecules, 2019-2030
10.7.1. In Vitro ADME Testing Services Market for Small Molecules, 2019-2030
10.7.2. In Vitro ADME Testing Services Market for Biologics, 2019-2030
10.8. In Vitro ADME Testing Services Market: Distribution by Therapeutic Areas, 2019-2030
10.8.1. In Vitro ADME Testing Services Market for Blood Disorders, 2019-2030
10.8.2. In Vitro ADME Testing Services Market for Cardiovascular Disorders, 2019-2030
10.8.3. In Vitro ADME Testing Services Market for Gastrointestinal and Digestive Disorders, 2019-2030
10.8.4. In Vitro ADME Testing Services Market for Hormonal Disorders, 2019-2030
10.8.5. In Vitro ADME Testing Services Market for Infectious Diseases, 2019-2030
10.8.6. In Vitro ADME Testing Services Market for Immunological Disorders, 2019-2030
10.8.7. In Vitro ADME Testing Services Market for Mental Disorders, 2019-2030
10.8.8. In Vitro ADME Testing Services Market for Metabolic Disorders, 2019-2030
10.8.9. In Vitro ADME Testing Services Market for Neurological Disorders, 2019-2030
10.8.10. In Vitro ADME Testing Services Market for Cancers, 2019-2030
10.8.11. In Vitro ADME Testing Services Market for Respiratory Disorders, 2019-2030
10.8.12. In Vitro ADME Testing Services Market for Skin Disorders, 2019-2030
10.8.13. In Vitro ADME Testing Services Market for Urogenital Disorders, 2019-2030
10.8.14. In Vitro ADME Testing Services Market for Other Disorders, 2019-2030
10.8.15. In Vitro ADME Testing Services Market: Market Attractiveness Analysis by Therapeutic Areas, 2019-2030
10.9. In Vitro ADME Testing Services Market: Distribution by Type of Sponsors, 2019-2030
10.9.1. In Vitro ADME Testing Services Market for Industry Players, 2019-2030
10.9.2. In Vitro ADME Testing Services Market for Non-Industry Players, 2019-2030

11. CONCLUSION

11.1. In Vitro ADME Studies Conducted During the Early Stages of Drug Development has Demonstrated the Potential to Improve the Probability of Success in Clinical Trials
11.2. Several CROs Offer Services for In Vitro ADME Testing; Most such Companies are based in North America and Europe
11.3. The Market is Dominated by Players having Vast In Vitro ADME Testing Portfolios; Drug Metabolism-related Assays Represent a Major Fraction of Services
11.4. Stakeholders are Actively Expanding their Existing Capabilities to Cater to the Increasing Demand; this is Evident in Number of Acquisitions Reported over the Past Decade
11.5. Owing to the Benefits of Outsourcing, the In Vitro ADME testing Services Market is Expected to Grow at a Healthy Pace in the Foreseen Future

12. EXECUTIVE INSIGHTS

12.1. Chapter Overview
12.2. 490 BioTech
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Dan Close, Chief Scientific Officer
12.3. JRF Global
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Sridhar Iyer, Director and Global Head, Business Development and Sarang Gorte, Assistant Manager, Business Development

13. APPENDIX 1: TABULATED DATA14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

Table 3.1 List of Assays Performed During ADME Studies
Table 5.1 In Vitro ADME Testing Services: List of Industry Players
Table 5.2 In Vitro ADME Testing Service Providers: Information on Type of In Vitro ADME Testing Services
Table 5.3 In Vitro ADME Testing Service Providers: Information on Type of Molecule
Table 5.4 In Vitro ADME Testing Service Providers: Information on Type of Clientele
Table 5.5 In Silico ADME Testing Services: List of Industry Players
Table 6.1 In Vitro ADME Testing Services: List of Companies Profiled
Table 6.2 AMRI: Key Highlights
Table 6.3 AMRI: Recent / Past Trends and Future Outlook
Table 6.4 Charles River Laboratories: Key Highlights
Table 6.5 Charles River Laboratories: Recent / Past Trends and Future Outlook
Table 6.6 BioDuro: Key Highlights
Table 6.7 BioDuro: Recent / Past Trends and Future Outlook
Table 6.8 RTI International: Key Highlights
Table 6.9 RTI International: Recent / Past Trends and Future Outlook
Table 6.10 Eurofins Scientific: Key Highlights
Table 6.11 Eurofins Scientific: Recent / Past Trends and Future Outlook
Table 6.12 Evotec: Key Highlights
Table 6.13 Evotec: In Vitro ADME Assays Offered
Table 6.14 Evotec: Recent / Past Trends and Future Outlook
Table 6.15 Galapagos: Key Highlights
Table 6.16 Galapagos: Recent / Past Trends and Future Outlook
Table 6.17 Tecan Group: Key Highlights
Table 6.18 Tecan Group: Recent / Past Trends and Future Outlook
Table 6.19 GVK Biosciences: Key Highlights
Table 6.20 GVK Biosciences: Recent / Past Trends and Future Outlook
Table 6.21 Pharmaron: Key Highlights
Table 6.22 Pharmaron: Recent / Past Trends and Future Outlook
Table 6.23 Sai Life Sciences: Key Highlights
Table 6.24 Sai Life Sciences: Recent / Past Trends and Future Outlook
Table 6.25 Shanghai Medicilon: Key Highlights
Table 6.26 Shanghai Medicilon: Recent / Past Trends and Future Outlook
Table 6.27 Syngene International: Key Highlights
Table 6.28 Syngene International: Recent / Past Trends and Future Outlook
Table 6.29 WuXi AppTec: Key Highlights
Table 6.30 WuXi AppTec: Recent / Past Trends and Future Outlook
Table 7.1 Benchmark Analysis: Peer Groups
Table 8.1 In Vitro ADME Testing Services: Mergers and Acquisitions
Table 8.2 In Vitro ADME Testing Services: Information on Key Value Drivers of Acquisitions
Table 8.3 Key Acquisitions: Deal Multiples
Table 9.1 USFDA: Guidance Documents for Non-Clinical Studies
Table 9.2 EMA: Guidance Documents for Non-Clinical Studies
Table 9.3 MHLW: Guidance Documents for Non-Clinical Studies
Table 9.4 In Vitro ADME Testing Service Providers: Information on Regulatory Approval
Table 12.1 490 BioTech: Key Highlights
Table 12.2 JRF Global: Key Highlights
Table 13.1 Reasons for Attrition in Drug Development
Table 13.2 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment
Table 13.3 In Vitro ADME Testing Service Providers: Distribution by Geographical Location
Table 13.4 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment and Geography
Table 13.5 In Vitro ADME Testing Service Providers: Distribution by Company Size
Table 13.6 In Vitro ADME Testing Service Providers: Distribution by Type of Service Offerings
Table 13.7 In Vitro ADME Testing Service Providers: Distribution by Type of In Vitro ADME Testing Services
Table 13.8 In Vitro ADME Testing Service Providers: Distribution by Type of Absorption Assays
Table 13.9 In Vitro ADME Testing Service Providers: Distribution by Type of Distribution Assays
Table 13.10 In Vitro ADME Testing Service Providers: Distribution by Type of Metabolism Assays
Table 13.11 In Vitro ADME Testing Service Providers: Distribution by Type of Molecule
Table 13.12 In Vitro ADME Testing Service Providers: Distribution by Type of Clientele
Table 13.13 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Table 13.14 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Table 13.15 Charles River Laboratories: Annual Revenues, 2013-Q3 2018 (USD Billion)
Table 13.16 RTI International: Annual Revenues, 2013-2017 (USD Million)
Table 13.17 Eurofins Scientific: 2013-Q3 2018 Annual Revenues (EUR Billion)
Table 13.18 Evotec: Annual Revenues, 2013–Q1 2018 (EUR Million)
Table 13.19 Evotec: Revenues by Business Segments, 2017 (EUR Million)
Table 13.20 Galapagos: Annual Revenues, 2013-Q3 2018 (EUR Million)
Table 13.21 Tecan Group: Annual Revenues, 2013-H1 2018 (CHF Million)
Table 13.22 Syngene International: Annual Revenues, 2012–H1 2018 (INR Million)
Table 13.23 WuXi AppTec: Annual Revenues, 2011-9M 2015 (USD Million)
Table 13.24 Benchmark Analysis: Distribution of Companies by Geographical Location and Company Size
Table 13.25 Benchmark Analysis: Peer Group I
Table 13.26 Benchmark Analysis: Peer Group II
Table 13.27 Benchmark Analysis: Peer Group III
Table 13.28 Benchmark Analysis: Peer Group IV
Table 13.29 Benchmark Analysis: Peer Group V
Table 13.30 Benchmark Analysis: Peer Group VI
Table 13.31 Benchmark Analysis: Peer Group VII
Table 13.32 Benchmark Analysis: Peer Group VIII
Table 13.33 Acquisitions: Year-Wise Cumulative Trend (2005-2018)
Table 13.34 Acquisitions: Regional Distribution
Table 13.35 Acquisitions: Intercontinental and Intracontinental Acquisitions
Table 13.36 Acquisitions: Ownership Change Matrix
Table 13.37 Acquisitions: Most Active Acquirers
Table 13.38 Acquisitions: Key Value Drivers
Table 13.39 Acquisitions: Heat Map Analysis by Key Value Drivers and Year of Acquisition
Table 13.40 Regulatory Landscape for In Vitro ADME Testing Service Providers: Analysis by Type of Regulatory Authorities
Table 13.41 Overall In Vitro ADME Testing Services Market, 2019-2030: Conservative Scenario (USD Billion)
Table 13.42 Overall In Vitro ADME Testing Services Market, 2019-2030: Base Scenario (USD Billion)
Table 13.43 Overall In Vitro ADME Testing Services Market, 2019-2030: Optimistic Scenario (USD Billion)
Table 13.44 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Conservative Scenario (USD Billion)
Table 13.45 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Base Scenario (USD Billion)
Table 13.46 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Optimistic Scenario (USD Billion)
Table 13.47 In Vitro ADME Testing Services Market, 2019-2030: North America, Conservative Scenario (USD Million)
Table 13.48 In Vitro ADME Testing Services Market, 2019-2030: North America, Base Scenario (USD Million)
Table 13.49 In Vitro ADME Testing Services Market, 2019-2030: North America, Optimistic Scenario (USD Million)
Table 13.50 In Vitro ADME Testing Services Market, 2019-2030: Europe, Conservative Scenario (USD Million)
Table 13.51 In Vitro ADME Testing Services Market, 2019-2030: Europe, Base Scenario (USD Million)
Table 13.52 In Vitro ADME Testing Services Market, 2019-2030: Europe, Optimistic Scenario (USD Million)
Table 13.53 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Conservative Scenario (USD Million)
Table 13.54 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Million)
Table 13.55 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Optimistic Scenario (USD Million)
Table 13.56 In Vitro ADME Testing Services Market: Share by Regions, 2019 and 2030
Table 13.57 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Conservative Scenario (USD Million)
Table 13.58 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Base Scenario (USD Million)
Table 13.59 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Optimistic Scenario (USD Million)
Table 13.60 In Vitro ADME Testing Services Market: Share by Type of Services, 2019 and 2030
Table 13.61 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Conservative Scenario (USD Million)
Table 13.62 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Base Scenario (USD Million)
Table 13.63 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Optimistic Scenario (USD Million)
Table 13.64 In Vitro ADME Testing Services Market: Share by Type of Assays, 2019 and 2030
Table 13.65 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Conservative Scenario (USD Billion)
Table 13.66 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Base Scenario (USD Billion)
Table 13.67 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Optimistic Scenario (USD Billion)
Table 13.68 In Vitro ADME Testing Services Market: Share by Type of Molecules, 2019 and 2030
Table 13.69 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Conservative Scenario (USD Million)
Table 13.70 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Base Scenario (USD Million)
Table 13.71 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Therapeutic Areas, Optimistic Scenario (USD Million)
Table 13.72 In Vitro ADME Testing Services Market, 2019-2030: Market Attractiveness Analysis by Therapeutic Areas (USD Million)
Table 13.73 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Conservative Scenario (USD Billion)
Table 13.74 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Base Scenario (USD Billion)
Table 13.75 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Optimistic Scenario (USD Billion)
Table 13.76 In Vitro ADME Testing Services Market: Share by Type of Sponsors, 2019 and 2030

List of Figures

Figure 3.1 Drug Discovery and Development Timeline
Figure 3.2 Pharmacokinetics Pathway of a Drug in Human Body
Figure 3.3 Comparison of Oral and Intravascular Drug Administration: Role of Hepatic Portal System
Figure 3.4 Reasons for Attrition in Drug Development
Figure 3.5 ADME Studies in Discovery and Preclinical Development
Figure 3.6 Drivers for In Vitro ADME Testing Studies
Figure 4.1 Guiding Models for Outsourcing
Figure 4.2 Key Characteristics of Transactional Outsourcing Model
Figure 4.3 Key Characteristics of Performance-based Outsourcing Model
Figure 4.4 Key Steps Leading to Outcomes-based Outsourcing Model
Figure 4.5 Factors Influencing Outsourcing Decisions
Figure 4.6 Key Considerations to Select a CRO Partner
Figure 4.7 Role of a CRO in Different Phases of Drug Development
Figure 4.8 End-to-End Integrated Services in Discovery and Preclinical Research
Figure 4.9 Benefits of Outsourcing ADME Testing Services
Figure 4.10 Challenges Related to Outsourcing ADME Testing Services
Figure 5.1 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment
Figure 5.2 In Vitro ADME Testing Service Providers: Distribution by Geographical Location
Figure 5.3 In Vitro ADME Testing Service Providers: Distribution by Year of Establishment and Geography
Figure 5.4 In Vitro ADME Testing Service Providers: Distribution by Company Size
Figure 5.5 In Vitro ADME Testing Service Providers: Distribution by Type of Service Offerings
Figure 5.6 In Vitro ADME Testing Service Providers: Distribution by Type of In Vitro ADME Testing Services
Figure 5.7 In Vitro ADME Testing Service Providers: Distribution by Type of Absorption Assays
Figure 5.8 In Vitro ADME Testing Service Providers: Distribution by Type of Distribution Assays
Figure 5.9 In Vitro ADME Testing Service Providers: Distribution by Type of Metabolism Assays
Figure 5.10 In Vitro ADME Testing Service Providers: Distribution by Type of Molecule
Figure 5.11 In Vitro ADME Testing Service Providers: Distribution by Type of Clientele
Figure 5.12 In Vitro ADME Testing Service Providers Logo Landscape: Distribution by Company Size and Location
Figure 6.1 AMRI: Annual Revenues, 2012-Q1 2017 (USD Million)
Figure 6.2 AMRI: Contract Revenues by Business Segments, 2012-2016 (USD Million)
Figure 6.3 AMRI: In Vitro ADME Testing Service Portfolio
Figure 6.4 Charles River Laboratories: Business Segments
Figure 6.5 Charles River Laboratories: Annual Revenues, 2013-Q3 2018 (USD Billion)
Figure 6.6 Charles River Laboratories: In Vitro ADME Testing Service Portfolio
Figure 6.7 BioDuro: In Vitro ADME Assays Offered
Figure 6.8 RTI International: Annual Revenues, 2013-2017 (USD Million)
Figure 6.9 RTI International: In Vitro ADME Testing Service Portfolio
Figure 6.10 Eurofins Scientific: 2013-Q3 2018 Annual Revenues (EUR Billion)
Figure 6.11 Eurofins Scientific: In Vitro ADME Testing Service Portfolio
Figure 6.12 Evotec: Annual Revenues, 2013–Q1 2018 (EUR Million)
Figure 6.13 Evotec: Revenues by Business Segments, 2017 (EUR Million)
Figure 6.14 Evotec: Drug Discovery Services
Figure 6.15 Galapagos: Annual Revenues, 2013-Q3 2018 (EUR Million)
Figure 6.16 Galapagos: In Vitro ADME Testing Service Portfolio
Figure 6.17 Tecan Group: Annual Revenues, 2013-H1 2018 (CHF Million)
Figure 6.18 Tecan Group: In Vitro ADME Testing Service Portfolio
Figure 6.19 GVK Biosciences: Business Segments
Figure 6.20 GVK Biosciences: In Vitro ADME Testing Service Portfolio
Figure 6.21 Pharmaron: In Vitro ADME Service Portfolio
Figure 6.22 Sai Life Sciences: In Vitro ADME Testing Service Portfolio
Figure 6.23 Shanghai Medicilon: In Vitro ADME Testing Service Portfolio
Figure 6.24 Syngene International: Annual Revenues, 2012–H1 2018 (INR Million)
Figure 6.25 Syngene International: In Vitro ADME Testing Service Portfolio
Figure 6.26 WuXi AppTec: Annual Revenues, 2011-9M 2015 (USD Million)
Figure 6.27 WuXi AppTec: In Vitro ADME Testing Service Portfolio
Figure 7.1 Benchmark Analysis: Distribution of Companies by Geographical Location and Company Size
Figure 7.2 Benchmark Analysis: Peer Group I
Figure 7.3 Benchmark Analysis: Peer Group II
Figure 7.4 Benchmark Analysis: Peer Group III
Figure 7.5 Benchmark Analysis: Peer Group IV
Figure 7.6 Benchmark Analysis: Peer Group V
Figure 7.7 Benchmark Analysis: Peer Group VI
Figure 7.8 Benchmark Analysis: Peer Group VII
Figure 7.9 Benchmark Analysis: Peer Group VIII
Figure 7.10 Benchmark Analysis: Comparison Across Peer Groups
Figure 8.1 Acquisitions: Year-Wise Cumulative Trend (2005-2018)
Figure 8.2 Acquisitions: Regional Distribution
Figure 8.3 Acquisitions: Intercontinental and Intracontinental Acquisitions
Figure 8.4 Acquisitions: Ownership Change Matrix
Figure 8.5 Acquisitions: Most Active Acquirers
Figure 8.6 Acquisitions: Key Value Drivers
Figure 8.7 Acquisitions: Heat Map Analysis by Key Value Drivers and Year of Acquisition
Figure 9.1 Regulatory Guidelines for Non-Clinical Studies
Figure 9.2 ICH: Regulatory and Industry Participants
Figure 9.3 ICH: Guidance Documents for Non-Clinical Studies
Figure 9.4 USFDA: GLP Guidelines for Non-Clinical Studies
Figure 9.5 Regulatory Landscape for In Vitro ADME Testing Service Providers: Analysis by Type of Regulatory Authorities
Figure 10.1 Overall In Vitro ADME Testing Services Market, 2019-2030: Base Scenario (USD Billion)
Figure 10.2 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Regions, Base Scenario (USD Billion)
Figure 10.3 In Vitro ADME Testing Services Market: Share by Regions, 2019 and 2030
Figure 10.4 In Vitro ADME Testing Services Market, 2019-2030: North America, Base Scenario (USD Billion)
Figure 10.5 In Vitro ADME Testing Services Market, 2019-2030: US, Base Scenario (USD Million)
Figure 10.6 In Vitro ADME Testing Services Market, 2019-2030: Canada, Base Scenario (USD Million)
Figure 10.7 In Vitro ADME Testing Services Market, 2019-2030: Europe, Base Scenario (USD Billion)
Figure 10.8 In Vitro ADME Testing Services Market, 2019-2030: Germany, Base Scenario (USD Million)
Figure 10.9 In Vitro ADME Testing Services Market, 2019-2030: France, Base Scenario (USD Million)
Figure 10.10 In Vitro ADME Testing Services Market, 2019-2030: UK, Base Scenario (USD Million)
Figure 10.11 In Vitro ADME Testing Services Market, 2019-2030: Italy, Base Scenario (USD Million)
Figure 10.12 In Vitro ADME Testing Services Market, 2019-2030: Spain, Base Scenario (USD Million)
Figure 10.13 In Vitro ADME Testing Services Market, 2019-2030: Rest of Europe, Base Scenario (USD Million)
Figure 10.14 In Vitro ADME Testing Services Market, 2019-2030: Asia-Pacific and Rest of the World, Base Scenario (USD Billion)
Figure 10.15 In Vitro ADME Testing Services Market, 2019-2030: Japan, Base Scenario (USD Million)
Figure 10.16 In Vitro ADME Testing Services Market, 2019-2030: China, Base Scenario (USD Million)
Figure 10.17 In Vitro ADME Testing Services Market, 2019-2030: India, Base Scenario (USD Million)
Figure 10.18 In Vitro ADME Testing Services Market, 2019-2030: Rest of the World, Base Scenario (USD Million)
Figure 10.19 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Services, Base Scenario (USD Million)
Figure 10.20 In Vitro ADME Testing Services Market: Share by Type of Services, 2019 and 2030
Figure 10.21 In Vitro ADME Testing Services Market for Absorption Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.22 In Vitro ADME Testing Services Market for Distribution Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.23 In Vitro ADME Testing Services Market for Metabolism Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.24 In Vitro ADME Testing Services Market for Excretion Testing, 2019-2030: Base Scenario (USD Million)
Figure 10.25 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Assays, Base Scenario (USD Million)
Figure 10.26 In Vitro ADME Testing Services Market: Share by Type of Assays, 2019 and 2030
Figure 10.27 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Caco-2 Permeability Assay, Base Scenario (USD Million)
Figure 10.28 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Protein Binding Assay, Base Scenario (USD Million)
Figure 10.29 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Metabolic Stability / Clearance Assay, Base Scenario (USD Million)
Figure 10.30 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Enzyme Induction Assay, Base Scenario (USD Million)
Figure 10.31 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Enzyme Inhibition Assay, Base Scenario (USD Million)
Figure 10.32 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Other Assays, Base Scenario (USD Million)
Figure 10.33 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Molecules, Base Scenario (USD Billion)
Figure 10.34 In Vitro ADME Testing Services Market: Share by Type of Molecules, 2019 and 2030
Figure 10.35 In Vitro ADME Testing Services Market for Small Molecules, 2019-2030: Base Scenario (USD Billion)
Figure 10.36 In Vitro ADME Testing Services Market for Biologics, 2019-2030: Base Scenario (USD Billion)
Figure 10.37 In Vitro ADME Testing Services Market for Blood Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.38 In Vitro ADME Testing Services Market for Cardiovascular Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.39 In Vitro ADME Testing Services Market for Gastrointestinal and Digestive Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.40 In Vitro ADME Testing Services Market for Hormonal Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.41 In Vitro ADME Testing Services Market for Infectious Diseases, 2019-2030: Base Scenario (USD Million)
Figure 10.42 In Vitro ADME Testing Services Market for Immunological Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.43 In Vitro ADME Testing Services Market for Mental Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.44 In Vitro ADME Testing Services Market for Metabolic Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.45 In Vitro ADME Testing Services Market for Neurological Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.46 In Vitro ADME Testing Services Market for Cancers, 2019-2030: Base Scenario (USD Million)
Figure 10.47 In Vitro ADME Testing Services Market for Respiratory Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.48 In Vitro ADME Testing Services Market for Skin Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.49 In Vitro ADME Testing Services Market for Urogenital Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.50 In Vitro ADME Testing Services Market for Other Disorders, 2019-2030: Base Scenario (USD Million)
Figure 10.51 In Vitro ADME Testing Services Market, 2019-2030: Market Attractiveness by Therapeutic Areas, Base Scenario (USD Million)
Figure 10.52 In Vitro ADME Testing Services Market, 2019-2030: Distribution by Type of Sponsors, Base Scenario (USD Billion)
Figure 10.53 In Vitro ADME Testing Services Market: Share by Type of Sponsors, 2019 and 2030
Figure 10.54 In Vitro ADME Testing Services Market for Industry Players, 2019-2030: Base Scenario (USD Billion)
Figure 10.55 In Vitro ADME Testing Services Market for Non-Industry Players, 2019-2030: Base Scenario (USD Billion)
Figure 11.1 Overall In Vitro ADME Testing Services Market, Conservative, Base and Optimistic Scenarios, 2019, 2024 and 2030 (USD Billion)

Executive Summary

Example Highlights

More than 90 CROs currently offer in vitro services for testing ADME properties of drug candidates. The market landscape is highly fragmented, featuring a mix of small-sized (less than 50 employees, 42%), mid-sized (51-200 employees, 17%), large (201-1,000 employees, 16%) and very large (more than 1,000 employees, 25%) companies. Examples of some very large players active in this domain, include (in alphabetical order) Charles River Laboratories, Citoxlab Group, Corning Life Sciences, Eurofins Scientific, Piramal Pharma Solutions, QPS, RTI International, Sigma-Aldrich (acquired by Merck), SRI International, Tecan Group and Unilabs Serving Pharma. On the other hand, players that have recently (since 2013) entered the market include (in alphabetical order) APhaD, Aravali Pharma & Lifesciences, Concept Life Sciences, Envigo, IONTOX, Neuro-Sys, Q2 Solutions and Touchstone Biosciences.
Majority of the aforementioned CROs (80%) are based in North America and Europe. However, a growing proportion of such players are situated in the Asia-Pacific region. Examples of large companies based in this region include (in alphabetical order, no selection criteria) ChemPartner, GVK Biosciences, JOINN Laboratories, JRF Global, Jubilant Biosys, Medicilon, Pharmaron, Sai Life Sciences, Suven Life Sciences, Syngene International, TCG Lifesciences, Viva Biotech and WuXi AppTec.
Of the total number of in vitro ADME service providers, over 85% companies claim to offer assays for drug metabolism testing, which include UGT / CYP enzyme inhibition / induction assays (73), metabolite profiling and screening / identification (60), metabolic stability / metabolic clearance (55), reaction phenotyping (36), metabolite production (21) and transporter interactions (20). Further, over 60 companies claim to have capabilities to conduct absorption and distribution related studies, respectively.
Around 55% of the CROs claim to have the necessary expertise to offer services for testing the absorption, distribution, metabolism profiles of drug molecules. Examples of popular companies that claim to offer the required expertise to evaluate the aforementioned parameters, include (in alphabetical order, no selection criteria) AMRI, CanAm Bioresearch, CEMSA, Galapagos, InrexTest, Novamass, PharmaCadence, Pharmacelsus, Pharmidex Pharmaceutical Services, Shanghai Medicilon, Signature Discovery and Q3 Analytical.
Over 35 instances of acquisitions have taken place in this domain over the last decade. Examples of companies that were recently acquired include (in reverse chronological order)SNBL USA’s preclinical business by Altasciences (August 2018), Optivia Biotechnology by BioIVT (July 2018), MetaSafe by Admescope (June 2018),Concord Biosciences by Frontage Laboratories (April 2018), MPI Research by Charles River Laboratories(April 2018) and SOLVO Biotechnology by Citoxlab Group (March 2018).
Driven by a rising number of candidate drugs that enter the discovery stage across various therapeutic areas, we expect the in vitro ADME testing services market to grow at an annualized rate of nearly ~6% between 2019 and 2030. Based on our estimates, therapies targeting various cancers are expected to be responsible for 46% of the revenues generated within the market by 2030; this is likely to be followed by candidates targeting neurological disorders (13%), immunological disorders (7%) and infectious diseases (5%).
North America (primarily the US) and Europe currently hold the larger share (in terms of revenues, over 70%) within the overall in vitro ADME testing services market. This is followed by the Asia-Pacific region and the rest of the world. Within Asia-Pacific, markets in China and Japan are expected to grow at a relatively faster rate (~7%) in the coming decade. We are led to believe that the abovementioned trend is not likely to change significantly in the foreseen future.

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews/surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current scenario within the in vitro ADME testing services market and its likely evolution in the short-mid and long term.
Chapter 3 provides an introduction to the overall drug discovery process, with details on the time taken for a drug to traverse through the various stages of drug development and into the market. It includes an overview of ADME testing, featuring a detailed discussion on the significance of evaluating various ADME parameters within the drug discovery and development process. Further, the chapter presents insights on the benefits of carrying out ADME testing at early stages of drug development. It also features details related to various contract services that can be availed by industry stakeholders seeking to outsource ADME testing.
Chapter 4 features a detailed discussion on the various outsourcing related business models that are commonly adopted by the industry stakeholders in relation to ADME testing. The chapter includes a list of factors that drive sponsors to outsource their ADME testing operations. It also highlights several key parameters that sponsors need to take into consideration while choosing a CRO partner. The chapter features an elaborate discussion on the benefits of outsourcing ADME services, along with the affiliated risks and challenges.
Chapter 5 provides a comprehensive view on the global landscape of in vitro ADME testing service providers. It includes information related to over 90 CROs that claim to offer in vitro ADME services, featuring in-depth analyses of the players based on their year of establishment, headquarter location(s), company size, type of additional service(s) offered, range of assays offered within in vitro ADME service portfolio, type of molecule(s), and type of clientele. The chapter also includes a list of 70 players offering in silico ADME services. In addition, it also features a logo landscape of the players that claim to offer in vitro ADME services, distributed on the basis of the location of their respective headquarters and company size.
Chapter 6 features detailed profiles of key CROs that claim to offer in vitro ADME testing services, across different geographies. Each company profile includes a brief overview of the company, financial information (if available), information on in vitro ADME service(s) capabilities, and a comprehensive future outlook.
Chapter 7 presents a benchmark analysis of the various players engaged in this domain. It highlights the capabilities of the companies in terms of their expertise across various services related to in vitro ADME testing. The analysis allows companies to compare their existing capabilities within and beyond their respective peer groups, and thereby, providing a means for stakeholders to identify ways to gain a competitive edge in the industry.
Chapter 8 features a detailed analysis of the mergers and acquisitions that have taken place in this space, highlighting the trend in the number of companies acquired from 2005 to 2018. The analysis also features an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.
Chapter 9 features information on the regulatory guidelines that have been laid down by key regulatory bodies/organizations, specific to ADME testing in the pharmaceutical industry. These are EMA, ICH, MHLW, OECD, USFDA and WHO.
Chapter 10 features a comprehensive market forecast, highlighting the future potential of in vitro ADME testing services market till 2030. The projected opportunity has been further analyzed to develop a better perspective related to its distribution across [A] different global regions (North America, Europe, Asia-Pacific and rest of the world), [B] type of services (absorption, distribution, metabolism and excretion), [C] type of assays (across 5+ categories), [D] type of molecule(s) (biologics and small molecules), [E] type of sponsor company (pharmaceutical / biotechnology companies and academic / research institutes) and [F] therapeutic areas (across 10+ categories).
Chapter 11 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the biopharmaceutical industry.
Chapter 12 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Dan Close (Chief Scientific Officer, 490 BioTech), and Sridhar Iyer (Director and Global Head, Business Development, JRF Global) and Sarang Gorte (Assistant Manager, Business Development, JRF Global).
Chapter 13 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 14 is an appendix, which contains the list of companies and organizations mentioned in the report.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

490 BioTech
Aaranya Biosciences
AbbVie
Accelera
Advanced Chemistry Development Labs
Admescope
ADMETRx
Advancell Advanced In Vitro Cell Technologies
Agilux Laboratories
Allesh Biosciences Labs
Altasciences
AMRI
Analiza
Antengene
APEIRON Biologics
APhaD
Apredica
Aptuit
Aragen Bioscience
Aravali Pharma & Lifesciences
Asahi Kasei Pharma
Astellas Analytical Science Laboratories
AstraZeneca
Aurigon
Aurora Fine Chemicals
Avistron Chemistry Services
Baxter
Biaffin
Bienta
BioAscent
Biocon
BioDuro
BioIVT
Bionomics
Biotech Investment Group
Biotranex
BLIRT
BloodCenter of Wisconsin
Blue Stream Laboratories
BOC Sciences
Brains On-Line
BRI Biopharmaceutical Research
Brunswick Labs
Caliper Life Sciences
Calvert Laboratories
CanAm Bioresearch
Cangenix
CapEval Pharma
Carna Biosciences
Carrick Therapeutics
CeeTox
Celgene
Cellumen
Celsis In Vitro Technologies
Celsis International
CEMSA - Center for Applied Mass Spectrometry
Charles River Laboratories
ChemBio Discovery Solutions
ChemDiv
ChemModeling
ChemoGenics BioPharma
Chemotargets
ChemPartner
Citoxlab Group
Clinical Research Laboratories
Cloud Pharmaceuticals
Colorado Computational
Comparative Biosciences
CompChem Solutions
Concept Life Sciences
Concord Biosciences
Corning Life Sciences
Covance
CR Medicon
Creative Animodel
Creative Biolabs
Creative Biostructure
Crelux
Crucell
Cyclica
Cyprotex
Dermscan
DiaSorin
Discover Drugs
Distributed Bio
Domainex
Drik
eADMET
Eagle Pharmaceuticals
ECOSUR
EMD Millipore
Enamine
Entelos
Envigo
EnvironeX Group
Eurofins Scientific
Eurofins Cerep
European Federation of Pharmaceutical Industries and Associations
Eurosafe
Evolvus
Evotec
Excelra Knowledge Solutions
Exscientia
Fidelta
Formex
Frontage Laboratories
Gadea Pharmaceutical Group
Galapagos
Genentech
GenPharm Tox Biotech
Gfree Bio
Gilead Sciences
Greenpharma
GSK
GTCR
GVK Biosciences
HarkerBIO
HD Biosciences
Health Economics Research Centre
Icagen
IDSC
ImaBiotech
In Vitro ADMET Laboratories
Innovative Informatica Technologies
Inpharmatica
InrexTest
INSERM
International Resources Group
INVITEK
IONTOX
IOTA Pharmaceuticals
Japan Pharmaceutical Manufacturers Association
Janssen Therapeutics
JOINN Laboratories
JPT Peptide Technologies
JRF GLOBAL
Jubilant Biosys
Kirklees Biosciences
KWS BioTest
LabCorp
Labo Van Poucke
Laxai Avanti Life Sciences
LegoChem Biosciences
Longthera Pharmaceuticals
Mascot Industries
MasiMax Resources
Mayo Clinic
Medisyn Technologies
Merck
MetaSafe
Metrion Biosciences
MicroConstants
Mind the Byte
Molcode
Molsoft
MorphoSys
MPI Research
MTTlab
Nanolab Technologies
National Institute of Allergy and Infectious Disease
National Institutes of Health
Neuro-Sys
NMDL-LCPL
Notox
NovaData Solutions
Novamass
NovaMechanics
Novartis
Novo Informatics
NuChem Therapeutics
Nuevolution
NuGEN Technologies
Numerate
Oncodesign
Optivia Biotechnology
Oroxcell
Oxford Bioscience Partners
Panlabs Biologics
PathoQuest
PerkinElmer
Petra Pharma
Pfizer
PharmaCadence
Pharmacelsus
Pharmaceuticals and Medical Devices Agency
Pharmaceutical Product Development
Pharmaron
Pharmidex Pharmaceutical Services
PharmOptima
PHAST
Piramal Pharma Solutions
Porton Pharma Solutions
Preclinical GPS
Prestwick Chemical
Prime European Therapeuticals
Princeton BioMolecular Research
Profacgen
ProSciens
Prosilico
ProtoQSAR
ProXyChem
Q2 Solutions
Q3 Analytical
Qualyst Transporter Solutions
Quantum Hi-Tech
Quintara Discovery
Quotient Bioresearch
ReadyCell
Rebexsess Discovery Chemistry
Red Glead Discovery
Regulus Therapeutics
ResearchPoint Global
Rosa
RTI International
Sai Life Sciences
Sandexis
Sanofi
Schrödinger
Sekisui Medical
Sekisui XenoTech
Selcia
Selvita
Shanghai ChemPartner
Shanghai Medicilon
Shechter Computational Solutions
Shire
Sigma-Aldrich
SilcsBio
Simulations Plus
SNBL USA
SOLVO Biotechnology
Spectris
SPEware
SRI International
Strand Life Sciences
Suven Life Sciences
Sygnature Discovery
Syngene
Synovo
Syntegrity Group
TCG Lifesciences
Tecan
TestAmerica
TetraQ
The Carlyle Group
The Institute for Transfusion Medicine
The Michael J Fox Foundation
Touchstone Biosciences
TPG Capital
Triskelion
Unilabs
University of California
University of Pittsburgh
Vanta Bioscience
Villapharma Research
Vipragen Biosciences
Vitalant Research Institute
Viva Biotech
Vivo Bio Tech
Vivotecnia
WIL Research Laboratories
Wildcard Pharmaceutical Consulting
WuXi AppTec
Xceleron
XenoBiotic Laboratories
Xenometrics
XenoTech
XtalPi
Zumutor Biologics

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€3926EUR$3,999USD£3,265GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€7853EUR$7,999USD£6,531GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15707EUR$15,999USD£13,062GBP

Table of Contents

Executive Summary

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

In-Vitro Toxicology Testing Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023-2031

in-vitro Toxicology Testing Market Size, Share & Trends Analysis Report by Technology (Cell Culture, High Throughput), End-use, Application, Method (Cellular Assay), Product, Region, and Segment Forecasts, 2024-2030

In-Vitro Toxicology Testing Market by Technology, Method, Application, End-User Industry - Global Forecast 2025-2030

In-Vitro Diagnostics Market by Component, Technology, Specimen, Application, End User - Global Forecast 2025-2030

in-Vitro Toxicology Testing Global Market Report 2024